Innate Pharma (IPHYF) Short Interest Ratio & Short Volume $2.90 0.00 (0.00%) As of 04/1/2025 Add Compare Share Share Short Interest Stock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestBuy This Stock Innate Pharma Short Interest DataInnate Pharma (IPHYF) has a short interest of 900 shares, representing 0.00% of the float (the number of shares available for trading by the public). This marks a ∞ increase in short interest from the previous month. The short interest ratio (days to cover) is 0.0, indicating that it would take 0.0 days of the average trading volume of 0 shares to cover all short positions.Current Short Interest900 sharesPrevious Short Interest0 sharesChange Vs. Previous Month+∞Dollar Volume Sold Short$2,610.00Short Interest Ratio0.0 Days to CoverLast Record DateMarch 15, 2025Outstanding Shares80,210,000 sharesShort Percent of Float0.00%Today's Trading Volume0 sharesAverage Trading Volume0 sharesToday's Volume Vs. AverageNaN Short Selling Innate Pharma? Sign up to receive the latest short interest report for Innate Pharma and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIPHYF Short Interest Over TimeIPHYF Days to Cover Over TimeIPHYF Percentage of Float Shorted Over Time Remove Ads Innate Pharma Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/2025900 shares $2,610.00 No Change0.0%0 $2.90 2/15/20251,600 shares $4,640.00 +220.0%0.0%0 $2.90 1/31/2025500 shares $1,450.00 No ChangeN/A0 $2.90 1/15/2025500 shares $1,450.00 No ChangeN/A0 $2.90 12/31/2024500 shares $1,450.00 -94.1%N/A5 $2.90 12/15/20248,400 shares $24,360.00 +425.0%N/A21 $2.90 11/30/20241,600 shares $2,048.00 -61.9%N/A0 $1.28 11/15/20244,200 shares $5,376.00 -14.3%N/A42 $1.28 10/31/20244,900 shares $11,000.50 -17.0%N/A0 $2.25 10/15/20245,900 shares $13,245.50 -1.7%N/A0 $2.25 Get the Latest News and Ratings for IPHYF and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. 9/30/20246,000 shares $13,470.00 +22.5%N/A10 $2.25 9/15/20244,900 shares $11,270.00 No ChangeN/A0 $2.30 8/31/20244,900 shares $11,270.00 -21.0%N/A24.5 $2.30 8/15/20246,200 shares $13,020.00 -8.8%N/A12.4 $2.10 7/31/20246,800 shares $13,124.68 +23.6%N/A0 $1.93 7/15/20245,500 shares $10,615.55 No ChangeN/A55 $1.93 6/30/20245,500 shares $13,695.00 -30.4%N/A0 $2.49 6/15/20247,900 shares $19,671.00 +43.6%N/A7.2 $2.49 5/31/20245,500 shares $12,100.00 No ChangeN/A55 $2.20 5/15/20245,500 shares $12,100.00 -6.8%N/A2.5 $2.20 4/30/20245,900 shares $15,635.00 -1.7%N/A0 $2.65 4/15/20246,000 shares $15,900.00 +3.5%N/A60 $2.65 3/31/20245,800 shares $14,964.00 No ChangeN/A29 $2.58 3/15/20245,800 shares $14,152.00 +1.8%N/A58 $2.44 2/29/20245,700 shares $16,188.00 No ChangeN/A0 $2.84 2/15/20245,700 shares $16,188.00 -5.0%N/A0 $2.84 1/15/20244,800 shares $13,632.00 +108.7%N/A48 $2.84 12/31/20232,300 shares $6,532.00 -48.9%N/A4.5 $2.84 12/15/20234,500 shares $11,475.00 +650.0%N/A22.5 $2.55 11/30/2023600 shares $1,434.00 +500.0%N/A0 $2.39 11/15/2023100 shares $239.00 No ChangeN/A1 $2.39 10/15/20239,800 shares $22,625.26 +9,700.0%N/A19.6 $2.31 9/30/2023100 shares $300.00 No ChangeN/A0 $3.00 8/31/202311,600 shares $33,698.00 +11,500.0%N/A43.5 $2.91 8/15/2023100 shares $291.00 -75.0%N/A1 $2.91 7/31/2023400 shares $1,196.00 No ChangeN/A4 $2.99 7/15/2023400 shares $1,232.00 +33.3%N/A4 $3.08 6/30/2023300 shares $1,008.00 +200.0%N/A3 $3.36 6/15/2023100 shares $334.00 -80.0%N/A0.3 $3.34 5/31/2023500 shares $1,465.00 +400.0%N/A0 $2.93Brace Yourself for Jeff Bezos’ “Amazon Helios” (Ad)Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.Take these three steps to prepare. 5/15/2023100 shares $293.00 -75.0%N/A1 $2.93 4/30/2023400 shares $1,152.00 +100.0%N/A4 $2.88 4/15/2023200 shares $542.00 -97.8%N/A0 $2.71 3/31/20239,200 shares $24,932.00 -27.6%N/A92 $2.71 3/15/202312,700 shares $39,497.00 +1,487.5%N/A63.5 $3.11 2/28/2023800 shares $2,344.00 +14.3%N/A8 $2.93 2/15/2023700 shares $2,408.00 -95.5%N/A0 $3.44 1/31/202315,700 shares $54,008.00 +15,600.0%N/A52.3 $3.44 1/15/2023100 shares $347.00 -97.1%N/A0.3 $3.47 12/30/20223,500 shares $11,445.00 -60.7%N/A0.7 $3.27 12/15/20228,900 shares $20,648.00 +8,800.0%N/A22.3 $2.32 11/30/2022100 shares $218.88 -90.9%N/A1 $2.19 11/15/20221,100 shares $2,519.00 -80.4%N/A1.1 $2.29 10/31/20225,600 shares $11,697.84 +30.2%N/A56 $2.09 10/15/20224,300 shares $8,901.00 +4,200.0%N/A2.3 $2.07 9/30/2022100 shares $193.00 -66.7%N/A1 $1.93 9/15/2022300 shares $780.00 -97.7%N/A1.5 $2.60 8/31/202212,800 shares $35,840.00 +236.8%N/A8.5 $2.80 8/15/20223,800 shares $10,564.00 +11.8%N/A12.7 $2.78 7/31/20223,400 shares $10,744.00 +6.3%N/A34 $3.16 7/15/20223,200 shares $8,640.00 -3.0%N/A32 $2.70 6/30/20223,300 shares $8,580.00 -15.4%N/A1.2 $2.60 6/15/20223,900 shares $10,803.00 -54.7%N/A39 $2.77 5/31/20228,600 shares $24,338.00 +34.4%N/A86 $2.83 5/15/20226,400 shares $18,112.00 -4.5%N/A32 $2.83 4/30/20226,700 shares $18,391.50 +8.1%N/A67 $2.75 4/15/20226,200 shares $18,910.00 +51.2%N/A12.4 $3.05 3/31/20224,100 shares $14,186.00 -93.9%N/A41 $3.46 3/15/202267,000 shares $241,870.00 -10.8%N/A0 $3.61 2/28/202275,100 shares $271,111.00 +1,004.4%N/A751 $3.61 2/15/20226,800 shares $25,228.00 -70.0%N/A5.7 $3.71 1/31/202222,700 shares $85,579.00 +57.6%N/A37.8 $3.77 1/15/202214,400 shares $62,640.00 +5.1%N/A0 $4.35 12/31/202113,700 shares $59,595.00 +407.4%N/A5.1 $4.35 12/15/20212,700 shares $13,743.00 -52.6%N/A1.4 $5.09 11/30/20215,700 shares $28,618.56 +1.8%N/A6.3 $5.02 11/15/20215,600 shares $28,000.00 -51.7%N/A3.1 $5.00 10/29/202111,600 shares $65,656.00 -6.5%N/A4.1 $5.66 10/15/202112,400 shares $73,160.00 +63.2%N/A6.5 $5.90 9/30/20217,600 shares $47,500.00 -26.2%N/A0.7 $6.25 9/15/202110,300 shares $58,504.00 -94.6%N/A0.7 $5.68 8/31/2021191,300 shares $679,115.00 -49.5%N/A956.5 $3.55 8/13/2021378,500 shares $1.22 million -0.1%N/A3785 $3.22 7/30/2021378,700 shares $1.19 million +0.2%N/A3787 $3.15 7/15/2021378,100 shares $1.23 million +0.0%N/A315.1 $3.25 6/30/2021378,000 shares $1.23 million No ChangeN/A315 $3.25 6/15/2021378,000 shares $1.34 million -0.5%N/A3780 $3.55 5/28/2021379,800 shares $1.44 million -10.3%N/A0 $3.80 5/14/2021423,400 shares $1.74 million +2.3%N/A4234 $4.11 4/30/2021414,000 shares $1.85 million +3.3%N/A828 $4.48Brace Yourself for Jeff Bezos’ “Amazon Helios” (Ad)Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical technology that could change society forever and make early investors rich.Take these three steps to prepare. 4/15/2021400,700 shares $1.80 million +1,627.2%N/A4007 $4.48 3/31/202123,200 shares $102,506.88 -94.2%N/A77.3 $4.42 3/15/2021401,900 shares $1.82 million 0.0%N/A4019 $4.53 2/26/2021402,000 shares $1.79 million -0.1%N/A1340 $4.46 2/12/2021402,300 shares $1.94 million -0.7%N/A365.7 $4.81 1/29/2021405,200 shares $1.75 million No ChangeN/A4052 $4.33 1/15/2021405,500 shares $1.91 million 0.0%N/A1013.8 $4.72 12/31/2020405,200 shares $1.72 million -0.1%N/A368.4 $4.24 12/15/2020405,500 shares $1.77 million 0.0%N/A1013.8 $4.36 11/30/2020405,600 shares $2.21 million -0.4%N/A450.7 $5.45 11/15/2020407,100 shares $1.81 million No ChangeN/A1017.8 $4.45 10/30/2020407,100 shares $1.51 million +0.2%N/A508.9 $3.70 10/15/2020406,300 shares $1.66 million -0.1%N/A677.2 $4.08 9/30/2020406,600 shares $1.55 million -3.1%N/A4066 $3.80 9/15/2020419,700 shares $1.73 million +3.3%N/A182.5 $4.13 8/31/2020406,200 shares $2.62 million No ChangeN/A2031 $6.45 8/14/2020406,200 shares $2.62 million +0.2%N/A1354 $6.44 7/31/2020405,500 shares $2.56 million No ChangeN/A0 $6.33 7/15/2020405,500 shares $2.56 million No ChangeN/A4055 $6.33 6/30/2020405,500 shares $2.46 million +1,897.5%N/A2027.5 $6.06 6/15/202020,300 shares $128,905.00 +0.5%N/A40.6 $6.35 5/29/202020,200 shares $125,846.00 -95.0%N/A0 $6.23 5/15/2020405,200 shares $2.86 million No ChangeN/A193 $7.07 4/30/2020405,200 shares $2.66 million No ChangeN/A4052 $6.57 4/15/2020405,200 shares $2.24 million 0.0%N/A405.2 $5.53 IPHYF Short Interest - Frequently Asked Questions What is Innate Pharma's current short interest? Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been closed out or covered. As of March 15th, traders have sold 900 shares of IPHYF short. 0.00% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest. What is a good short interest percentage for Innate Pharma? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.00% of Innate Pharma's floating shares are currently sold short. Is Innate Pharma's short interest increasing or decreasing? Innate Pharma saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 900 shares, an increase of ∞ from the previous total of 0 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Innate Pharma's short interest compare to its competitors? 0.00% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to Innate Pharma: Vir Biotechnology, Inc. (9.02%), Replimune Group, Inc. (13.60%), Anavex Life Sciences Corp. (31.75%), LENZ Therapeutics, Inc. (11.50%), Valneva SE (0.02%), MeiraGTx Holdings plc (2.74%), Immatics (7.49%), Opthea Limited (0.35%), Relay Therapeutics, Inc. (11.94%), Cullinan Therapeutics, Inc. (24.44%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($26.28 billion), iShares 20+ Year Treasury Bond ETF ($9.53 billion), MicroStrategy Incorporated ($8.50 billion), Apollo Global Management, Inc. ($4.86 billion), Super Micro Computer, Inc. ($4.85 billion), Charter Communications, Inc. ($4.28 billion), Capital One Financial Co. ($4.08 billion), AppLovin Co. ($3.82 billion), Canadian Natural Resources Limited ($3.78 billion), and Schlumberger Limited ($2.87 billion). View all of the most shorted stocks. What does it mean to sell short Innate Pharma stock? Short selling IPHYF is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Innate Pharma? A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHYF, which in turn drives the price of the stock up even further. How often is Innate Pharma's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHYF, twice per month. The most recent reporting period available is March, 15 2025. More Short Interest Resources from MarketBeat Related Companies Vir Biotechnology Short Interest Replimune Group Short Interest Anavex Life Sciences Short Interest LENZ Therapeutics Short Interest Valneva Short Interest MeiraGTx Short Interest Immatics Short Interest Opthea Short Interest Relay Therapeutics Short Interest Cullinan Therapeutics Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (OTCMKTS:IPHYF) was last updated on 4/2/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon Musk Is Investigating Fort KnoxWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored10X Bigger than AI, quantum, EVs, crypto, and robotics combined?World Economic Forum: "Arguably the Most Exciting Human Discovery Since Fire" Sam Altman, Bill Gates, and M...Stansberry Research | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IPHYF Stock Free IPHYF Stock Alerts